Abstract
Imaging of αvβ3 expression in malignant diseases has been extensively studied in the last years, mainly because the level of integrin αvβ3 expression might be a surrogate parameter of angiogenic activity. Most studies have been performed using preclinical tumor models but recently first results if imaging αvβ3 expression in patients have been published. The first approach used was the radiotracer approach with tracers for positron emission tomography (PET) like [18F]Galacto-RGD or tracers for single photon emission computed tomography (SPECT) like [99mTc]NC100692. In this article we will focus on the experimental design and methodology of PET imaging of αvβ3 expression with the tracer [18F]Galacto-RGD. Common difficulties and pitfalls in image acquisition and interpretation will be discussed. Finally, the performance of PET will be compared to other methods of imaging of αvβ3 expression, like magnetic resonance imaging, ultrasound, or optical imaging.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hood, J. D. and Cheresh, D. A. (2002) Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91–100.
Ruoslahti, E. (1996) RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697–715.
Xiong, J. P., Stehle, T., Zhang, R., et al. (2002) Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science 296, 151–5.
Cai, W. and Chen, X. (2006) Anti-angiogenic cancer therapy based on integrin αvβ3 antagonism. Anti-Cancer Agents Med. Chem. 6, 407–28.
Hynes, R. O. (2002) A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8, 918–21.
Kerbel, R. S. (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171–5.
Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–42.
Ruoslahti, E. and Pierschbacher, M. D. (1987) New perspectives in cell adhesion: RGD and integrins. Science 238, 491–7.
Haubner, R., Finsinger, D., and Kessler, H. (1997) Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew. Chem. Int. Ed. Engl. 36, 1374–89.
Haubner, R., Wester, H. J., Reuning, U., et al. (1999) Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med. 40, 1061–71.
Haubner, R., Kuhnast, B., Mang, C., Weber, W. A., Kessler, H., Wester, H. J., and Schwaiger, M. (2004, Jan-Feb) [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug. Chem. 15(1), 61–9.
Kenny, L. M., Coombes, R. C., Oulie, I., Contractor, K. B., Miller, M., Spinks, T. J., McParland., B., Cohen, P. S., Hui, A. M., Palmieri, C., Osman, S., Glaser, M., Turton, D., Al-Nahhas, A., and Aboagye, E. O. (2008, Jun) Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J. Nucl. Med. 49(6), 879–86.
Glaser, M., Morrison, M., Solbakken, M., Arukwe, J., Karlsen, H., Wiggen, U., Champion, S., Kindberg, G. M., and Cuthbertson, A. (2008, Apr) Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18F]fluorinated aldehyde-containing prosthetic groups. Bioconjug. Chem. 19(4), 951–7.
Beer, A. J., Haubner, R., Wolf, I., et al. (2006) PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging αvβ3 expression. J. Nucl. Med. 47, 763–9.
Stangier, I., Wester, H. J., Schwaiger, M., and Beer, A. J. (2007) Comparison of standardised uptake values and distribution volume for imaging of αvβ3 expression in breast cancer patients with [18F]Galacto-RGD PET. J. Nucl. Med. 48(S2), 406 (abstract).
Carson, R. E. (2003) Tracer kinetic modelling in PET. In Positron emission tomography – basic science and clinical practice, Valk, P. E., Bailey, D. L., Townsend, D. W., and Maisey, M. N., (Eds.), 2nd ed. Springer, London, pp. 147–80.
Slifstein, M. and Laruelle, M. (2001) Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl. Med. Biol. 28, 595–608.
Spilker, M. E., Sprenger, T., Valet, M., Henriksen, G., Wagner, K., Wester, H. J., et al. (2004) Quantification of [18F]diprenorphine kinetics in the human brain with compartmental and non-compartmental modeling approaches. Neuroimage 22, 1523–33.
Beer, A. J., Haubner, R., Goebel, M., et al. (2005) Biodistribution and pharmacokinetics of the αvβ3 selective tracer 18F Galacto-RGD in cancer patients. J. Nucl. Med. 46, 1333–41.
Schnell, O., Krebs, B., Wagner, E., Romagna, A., Beer, A. J., Grau, S. J., Thon, N., Goetz, C., Kretzschmar, H. A., Tonn, J. C., and Goldbrunner, R. H. (2008, Jul) Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 18(3), 378–86.
Beer, A. J., Haubner, R., Sarbia, M., Goebel, M., Luderschmidt, S., Grosu, A. L., Schnell, O., Niemeyer, M., Kessler, H., Wester, H. J., Weber, W. A., and Schwaiger, M. (2006) Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αvβ3 expresssion in man. Clin. Cancer Res. 12, 3942–9.
Beer, A. J., Grosu, A. L., Carlsen, J., Kolk, A., Sarbia, M., Stangier, I., Watzlowik, P., Wester, H. J., Haubner, R., and Schwaiger, M. (2007, Nov 15) [18F]Galacto-RGD PET for imaging of αvβ3 expression on neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13(22 Pt 1), 6610–6.
Beer, A. J., Lorenzen, S., Metz, S., Herrmann, K., Watzlowik, P., Wester, H. J., Peschel, C., Lordick, F., and Schwaiger, M. (2008, Jan) Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J. Nucl. Med. 49(1), 22–9.
Beer, A. J. and Schwaiger, M. (2008, Jun 4) Imaging of integrin αvβ3 expression. Cancer Metastasis Rev. 27, 631–44.
Makowski, M. R., Ebersberger, U., Nekolla, S., and Schwaiger, M. (2008, Mar 27) In vivo molecular imaging of angiogenesis, targeting αvβ3 integrin expression, in a patient after acute myocardial infarction. Eur. Heart J. 29, 2201.
Haubner, R., Weber, W. A., Beer, A. J., Vabuliene, E., Reim, D., Sarbia, M., Becker, K. F., Goebel, M., Hein, R., Wester, H. J., Kessler, H., and Schwaiger, M. (2005, Mar) Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2(3), e70.
Pichler, B. J., Kneilling, M., Haubner, R., Braumüller, H., Schwaiger, M., Röcken, M., and Weber, W. A. (2005, Jan) Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. J. Nucl. Med. 46(1), 184–9.
Bach-Gansmo, T., Danielsson, R., Saracco, A., Wilczek, B., Bogsrud, T. V., Fangberget, A., Tangerud, A., and Tobin, D. (2006, Sep) Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J. Nucl. Med. 47(9), 1434–9.
Weber, W. A. (2006) Positron emission tomography as an imaging biomarker. J. Clin. Oncol. 24(20), 3282–92.
Buck, A. K., Nekolla, S., Ziegler, S., Beer, A., Krause, B. J., Herrmann, K., Scheidhauer, K., Wester, H. J., Rummeny, E. J., Schwaiger, M., and Drzezga, A. (2008, Aug) Spect/Ct. J. Nucl. Med. 49(8), 1305–19.
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., and Li, K. C. (1998) Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nat. Med. 4, 623–6.
Winter, P. M., Caruthers, S. D., Kassner, A., et al. (2003) Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel αvβ3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 63, 5838–43.
Schmieder, A. H., Winter, P. M., Caruthers, S. D., et al. (2005) Molecular MR imaging of melanoma angiogenesis with αvβ3-targeted paramagnetic nanoparticles. Magn. Reson. Med. 53, 621–7.
Thorek, D. L., Chen, A. K., Czupryna, J., and Tsourkas, A. (2006) Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng. 34, 23–38.
Zhang, C., Jugold, M., Woenne, E. C., et al. (2007) Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 67, 1555–62.
Spuentrup, E. and Botnar, R. M. (2006) Coronary magnetic resonance imaging: visualization of vessel lumen and the vessel wall and molecular imaging of arteriotrombosis. Eur. Radiol. 16, 1–14.
Jaffer, F. A. and Weissleder, R. (2004) Seeing within: molecular imaging of the cardiovascular system. Circ. Res. 94, 433–45.
Ellegala, D. B., Leong-Poi, H., Carpenter, J. E., et al. (2003) Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to αvβ3. Circulation 108, 336–41.
Kumar, C. C., Nie, H., Rogers, C. P., et al. (1997) Biochemical characterization of the binding of echistatin to integrin αvβ3 receptor. J. Pharmacol. Exp. Ther. 283, 843–53.
Hughes, M. S., Marsh, J. N., Zhang, H., et al. (2006) Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo. IEEE Trans. Ultrason. Ferroelectr. Freq. Control 53, 1609–16.
Marsh, J. N., Partlow, K. C., Abendschein, D. R., Scott, M. J., Lanza, G. M., and Wickline, S. A. (2007) Molecular imaging with targeted perfluorocarbon nanoparticles: quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound Med. Biol. 33(6), 950–8.
Bloch, S. H., Dayton, P. A., and Ferrara, K. W. (2004) Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. IEEE Eng. Med. Biol. Mag. 23, 18–29.
Bremer, C., Bredow, S., Mahmood, U., et al. (2001) Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 221, 523–9.
Chen, X., Conti, P. S., and Moats, R. A. (2004) In vivo near-infrared fluorescence imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res. 64(21), 8009–14.
Jin, Z. H., Josserand, V., Foillard, S., Boturyn, D., Dumy, P., Favrot, M. C., and Coll, J. L. (2007) In vivo optical imaging of integrin αvβ3 in mice using multivalent or monovalent cRGD targeting vectors. Mol. Cancer 6, 41.
von Wallbrunn, A., Holtke, C., Zuhlsdorf, M., Heindel, W., Schafers, M., and Bremer, C. (2007) In vivo imaging of integrin αvβ3 expression using fluorescence-mediated tomography. Eur. J. Nucl. Med. Mol. Imaging 34(5), 745–54 (Epub 2006 Nov 28).
Jaffer, F. A. and Weissleder, R. (2005) Molecular imaging in the clinical arena. JAMA 293, 855–62.
Chen, X., Tohme, M., Park, R., Hou, Y., Bading, J. R., and Conti, P. S. (2004) Micro-PET imaging of αvβ3-integrin expression with 18F-labeled dimeric RGD peptide. Mol. Imaging 3, 96–104.
Zhang, X., Xiong, Z., Wu, X., et al. (2006) Quantitative PET imaging of tumor integrin αvβ3 expression with 18F-FRGD2. J. Nucl. Med. 47, 113–21.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Humana Press
About this protocol
Cite this protocol
Beer, A.J., Schwaiger, M. (2011). PET Imaging of αvβ3 Expression in Cancer Patients. In: Shah, K. (eds) Molecular Imaging. Methods in Molecular Biology, vol 680. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-901-7_13
Download citation
DOI: https://doi.org/10.1007/978-1-60761-901-7_13
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-900-0
Online ISBN: 978-1-60761-901-7
eBook Packages: Springer Protocols